Author

Matteo Loi

Observed name: Matteo loi

Institution: Johnson & Johnson (Netherlands)

Observed institutions: University of Cagliari, University of California, San Francisco, Johnson & Johnson (Netherlands)

OpenAlex ID: A5111601315

Occupational exposure to ionizing radiation and risk of lymphoma subtypes: results of the Epilymph European case-control study

2020 · Giannina Satta, Matteo Loi, et al. · Environmental Health · 7

Cardiac risk factors and cardiac events in patients with newly diagnosed amyloid light chain (AL) amyloidosis from the Phase 2 aquarius study of daratumumab (DARA) plus bortezomib, cyclophosphamide, and dexamethasone (D-VCd)

2025 · Vaishali Sanchorawala, Monique Minnema, et al. · Blood · 2

Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM): Final analysis of transplant-ineligible (TIE) pts in the phase 3 CEPHEUS study.

2026 · Saad Z. Usmani, Thierry Facon, et al. · Journal of Clinical Oncology · 1

Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS

2026 · Saad Z. Usmani, Thierry Facon, et al. · Journal of Clinical Oncology

PA-165 Efficacy and Safety of Daratumumab Plus VCd in Newly Diagnosed Amyloid Light-Chain Amyloidosis with Cardiac Involvement: A Pooled Analysis of Asian Patients from AMY2009 and AMY3001

2026 · Jin Lu, Minghui Zhao, et al. · Clinical Lymphoma Myeloma & Leukemia

OA-69 The Benefit of Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (DVRd) on Depth and Durability of Response in the Phase 3 CEPHEUS Trial: Updated Minimal Residual Disease Analysis

2026 · Sonja Zweegman, Nizar J. Bahlis, et al. · Clinical Lymphoma Myeloma & Leukemia

POSTER: MM-338: Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma: Final Analysis of Transplant-Ineligible Patients in the Phase 3 CEPHEUS Study

2026 · Saad Z Usmani, Thierry Facon, et al. · Clinical Lymphoma Myeloma & Leukemia

MM-338: Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma: Final Analysis of Transplant-Ineligible Patients in the Phase 3 CEPHEUS Study

2026 · Saad Z Usmani, Thierry Facon, et al. · Clinical Lymphoma Myeloma & Leukemia

Age and frailty analyses of transplant-ineligible (TIE) patients (pts) with newly diagnosed multiple myeloma (NDMM) in the phase 3 MAIA and CEPHEUS trials of daratumumab + lenalidomide-dexamethasone (Rd) and bortezomib-Rd (VRd).

2026 · Christopher P. Venner, Sonja Zweegman, et al. · Journal of Clinical Oncology

0484 Exposure to ionising radiation and risk of lymphoma subtypes: analysis of the epilymph results

2017 · Pierluigi Cocco, Matteo loi, et al.

Works count: 10

Citation count: 10

H-index: 2

I10-index: